Tolmar Australia Pty Ltd has been acquired by Mundipharma Pty Limited
Tolmar International Limited, the owner of Tolmar Australia Pty Limited, has sold the company to Mundipharma Pty Limited. Financial details have not been disclosed.
Tolmar Australia is the Australian subsidiary of Tolmar International Limited, a global pharmaceuticals group focused on the manufacturing and distribution of pharmaceutical products including uro-oncology products. Tolmar Australia held the exclusive distribution and marketing rights for Eligard in Australia and New Zealand, a leading PBS-reimbursed prostate cancer therapeutic.
Mundipharma is a global pharmaceutical company with a large presence in Australia. Mundipharma is a leader in the development and provision of medicines for pain including treatments for cancer care, ophthalmology, respiratory, hydration and first aid. In addition, it is a member of a global network of independent associated companies that are engaged in research, development, production and marketing of prescription medicines and consumer healthcare products. Mundipharma has global operations spanning Europe, Asia, New Zealand, Latin America, the Middle East and North Africa.
Tolmar International is a global pharmaceuticals group focused on urology and oncology products. Tolmar’s team of highly trained research scientists, chemists and engineers work to deliver treatments that advance patient care around the world.
Oaklins' team in Australia advised the seller in this transaction and ran a competitive and confidential sale process, managing interest from a broad range of global pharmaceutical companies, resulting in a successful result for the client. This deal demonstrates the team's ability to source and execute cross-border transactions generating interest on a global scale. This deal highlights the appeal of the Australian pharmaceuticals sector to international buyers.
相关交易
CARSO Group has acquired a majority stake in AQCF Group
CARSO Group, a leading provider of testing services, has acquired a majority stake in AQCF Group, a key player in the field of food safety.
更多信息Prestige Inhome Care has found a long-term strategic partner
Prestige Inhome Care has received a growth capital investment from Yorkway Private. The newly formed partnership will provide growth capital for geographic expansion, increasing Prestige’s range of services and potential future acquisitions. The investment in Prestige is in line with Yorkway’s mandate to invest in leading Australian mid-market companies with strong management teams, backed by significant growth tail winds, as is the case in the aged care industry.
更多信息Cara Care has been acquired by Mahana Therapeutics
Mahana Therapeutics Inc., renowned for its pioneering digital treatments targeting chronic health issues, has recently finalized the acquisition of Cara Care (HiDoc Technologies GmbH). Cara Care stands out as a premier digital health platform and an official digital health application (DiGA) dedicated to enhancing gut health. This acquisition, supported by key investors Lux Capital and Jazz Ventures Partners, perfectly aligns with Mahana’s expansion strategy.
更多信息